<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04769206</url>
  </required_header>
  <id_info>
    <org_study_id>202376</org_study_id>
    <nct_id>NCT04769206</nct_id>
  </id_info>
  <brief_title>Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans</brief_title>
  <official_title>Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim 1: To test the hypothesis that prolonged (3-month) treatment with galantamine&#xD;
      inhibits NADPH IsoLG-protein adducts formation and improves markers of endothelial cell (EC)&#xD;
      dysfunction in AAs.&#xD;
&#xD;
      Aim 1a: The investigators will determine if galantamine inhibits NADPH IsoLG-protein adducts&#xD;
      formation, superoxide production, and immune cell activation compared to placebo.&#xD;
&#xD;
      For this purpose, the investigators will study peripheral blood mononuclear cell (PBMC), a&#xD;
      critical source of systemic oxidative stress, collected from study participants.&#xD;
&#xD;
      Aim 1b: The investigators will determine if galantamine reduces intracellular Iso-LGs,&#xD;
      ICAM-1, and 3-nitrotyrosine, a marker of vascular oxidative stress, in ECs harvested from&#xD;
      study participants.&#xD;
&#xD;
      Specific Aim 2: To determine if prolonged (3-month) treatment with galantamine improves&#xD;
      endothelial dysfunction as measured by vascular reactivity in AAs. The investigators will&#xD;
      measure vascular reactivity in response to ischemia in two vascular beds: (a) in conduit&#xD;
      arteries (brachial artery) using brachial artery diameter flow-mediated dilation (FMD), and&#xD;
      (b) in the microvasculature (MBV) using contrast-enhanced ultrasonography in skeletal muscle.&#xD;
&#xD;
      This proposal will study a novel mechanism that could alter the oxidative and immunogenic&#xD;
      responses that contributes to endothelial dysfunction in AAs and will offer a potential&#xD;
      pathway for the development of more effective therapies aimed at decreasing the progression&#xD;
      of endothelial dysfunction to cardiovascular disease in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelial dysfunction, a pro-thrombotic, inflammatory condition that causes impaired&#xD;
      vascular reactivity is an early reversible step in the development of atherosclerosis and&#xD;
      cardiovascular disease (CVD). Multiple studies consistently shown that African Americans&#xD;
      (AAs) have impaired endothelial function compared to whites. African Americans also&#xD;
      experience disproportionately higher CV morbidity and 20% higher mortality than whites or&#xD;
      Hispanics. Endothelial dysfunction is caused by the overproduction of reactive oxygen species&#xD;
      (ROS), particularly superoxide which interferes with endothelial-derived nitric oxide&#xD;
      signaling pathways. One of the major sources of superoxide is NADPH oxidase; our previous&#xD;
      work found that activation of NADPH oxidase contributes to vascular oxidation through the&#xD;
      formation of highly immunogenic isolevuglandins (IsoLG-protein adducts) in peripheral&#xD;
      mononuclear cells (PBMCs), which stimulates antigen presenting cells (APC) and inflammatory&#xD;
      mediators. Inflammation and oxidative stress are modulated by the parasympathetic nervous&#xD;
      system (PNS). The investigators and others found that AAs have reduced PNS activity compared&#xD;
      with whites.&#xD;
&#xD;
      The investigators preliminary data in obese AA women found that stimulation of the PNS&#xD;
      cholinergic transmission with the acetylcholinesterase inhibitor, galantamine, blocked the&#xD;
      production of oxidative stress and inflammatory cytokines induced by lipids.&#xD;
&#xD;
      The overall goal of the current proposal is to determine if prolonged treatment with&#xD;
      galantamine improves endothelial dysfunction and vascular oxidative stress in AAs. For this&#xD;
      purpose, the investigators will conduct a proof-of-concept, blinded, randomized,&#xD;
      placebo-controlled study to test the effect of 3-month treatment with galantamine (16 mg/day)&#xD;
      on vascular oxidative stress and impaired vascular reactivity in AAs.&#xD;
&#xD;
      Specifically, the investigators will evaluate whether galantamine treatment inhibits the&#xD;
      activation of NADPH-IsoLG formation and the subsequent immunogenic responses in PBMCs.&#xD;
      Furthermore, the investigators will determine if galantamine decreases markers of oxidative&#xD;
      stress and inflammation in harvested endothelial cells (ECs) and improves vascular reactivity&#xD;
      in the same study subjects. The planned studies will provide a comprehensive assessment of&#xD;
      the mechanism underlying the effect of increased PNS cholinergic transmission on endothelial&#xD;
      dysfunction.&#xD;
&#xD;
      If the investigators' hypothesis is correct, and galantamine improves endothelial dysfunction&#xD;
      in AAs, a population with a high risk for CVD, they will discover a novel mechanism that&#xD;
      could alter the oxidative and immunogenic responses in this population and will offer a&#xD;
      potential pathway for the development of more effective therapies aimed at decreasing CVD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FMD</measure>
    <time_frame>From baseline to 3 months</time_frame>
    <description>flow mediated dilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NADPH activation in PBMC</measure>
    <time_frame>From baseline to 3 months</time_frame>
    <description>NADPH activation as measured by subunits p47phox/gp91 phox in PBMC</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Galantamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galantamine 16mg/day&#xD;
- titrating: 4mg once a day for 2 weeks, titrate to 8mg once a day for 2 weeks, then 8mg twice a day for 8 more weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (micro crystalline cellulose)&#xD;
- 1 pill once daily for 4 weeks, then 2 pills daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
    <description>4mg daily titrating up to 8mg twice a day</description>
    <arm_group_label>Galantamine</arm_group_label>
    <other_name>Razadyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 pill a day for 4 weeks, 2 pills a day for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. African American women and men&#xD;
&#xD;
          2. Age 18 to 60 years old&#xD;
&#xD;
          3. BMI &gt;28&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals with a history of physician diagnosed myocardial infarction, angina, heart&#xD;
             failure, stroke, or transient ischemic attack, or who had undergone an invasive&#xD;
             procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement,&#xD;
             pacemaker placement or other vascular surgeries)&#xD;
&#xD;
          2. Uncontrolled hypertension defined as persistent blood pressure &gt;140/90 despite the use&#xD;
             of anti-hypertensive agents.&#xD;
&#xD;
          3. Diabetes Mellitus type 1 or type 2, as defined by a fasting plasma glucose of 126&#xD;
             mg/dL or greater hemoglobin A1C (HbA1C) 6.5% or above or the use of anti-diabetic&#xD;
             medication&#xD;
&#xD;
          4. The use of nitrates.&#xD;
&#xD;
          5. The metabolism of galantamine is primarily through the cytochrome P450 system,&#xD;
             specifically the CYP2D6 and CYP3A4 isoenzymes. We will exclude subjects who have&#xD;
             impaired hepatic function and/or who are currently using strong inhibitors of CYP3A4&#xD;
             and CYP2D6 (e.g. ketoconazole and paroxetine, respectively).&#xD;
&#xD;
          6. Pregnancy or breast-feeding. Women of child-bearing potential will be required to have&#xD;
             undergone tubal ligation or to be using an oral contraceptive or barrier methods of&#xD;
             birth control.&#xD;
&#xD;
          7. Post-menopausal women.&#xD;
&#xD;
          8. The use of any other central or peripheral acetylcholinesterase inhibitor (donezepil&#xD;
             (Aricept(R)), pyridostigmine (Mestinon(R)), rivastigmine (Exelon(R)), tacrine&#xD;
             (Cognex(R)).&#xD;
&#xD;
          9. First, second or third-degree AV block detected during the screening visit with an ECG&#xD;
&#xD;
         10. Seizures or history of seizures.&#xD;
&#xD;
         11. Current smokers defined as those who smoked a cigarette in the last 30 days.&#xD;
&#xD;
         12. History of recurrent syncope.&#xD;
&#xD;
         13. History of serious neurologic disease such as cerebral hemorrhage, stroke, or&#xD;
             transient ischemic attack.&#xD;
&#xD;
         14. History of cardiac shunts.&#xD;
&#xD;
         15. Allergy to eggs or soy.&#xD;
&#xD;
         16. Impaired hepatic function (aspartate amino transaminase [AST] and/or alanine amino&#xD;
             transaminase [ALT] &gt;3.0 x upper limit of normal range)&#xD;
&#xD;
         17. Impaired renal function test (eGFR&lt;60 mL/min/1.73m2)&#xD;
&#xD;
         18. Anemia (hematocrit &lt;34%)&#xD;
&#xD;
         19. Ongoing substance abuse.&#xD;
&#xD;
         20. Treatment with any investigational drug in the one month preceding the study&#xD;
&#xD;
         21. Mental conditions rendering a subject unable to understand the nature, scope and&#xD;
             possible consequences of the study&#xD;
&#xD;
         22. Inability to comply with the protocol, e.g. uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyndya Shibao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cyndya Shibao, MD</last_name>
    <phone>615-936-4584</phone>
    <email>cyndya.shibao@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wendi Welch</last_name>
    <phone>615-421-2998</phone>
    <email>wendi.m.welch@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendi Welch</last_name>
      <email>wendi.m.welch@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Cyndya A Shibao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annet Kirabo, DVM PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Cyndya Shibao, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>African American</keyword>
  <keyword>Flow-mediated dilation (FMD)</keyword>
  <keyword>Vascular Oxidative Stress</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

